Unrevealing the Role of miRNA in Successful TNBC Treatment: A Pilot Study to Explore the Chemotherapy Drugs for Timely Treatment of TNBC

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Poulami Sarkar, Rashmi Chowdhary, Ashish Kumar Yadav, Neha Arya, Bharti Pandya, Vinay Kumar, J. Kanwar, Arshi Siddiqui, Roji Begum Khan
{"title":"Unrevealing the Role of miRNA in Successful TNBC Treatment: A Pilot Study to Explore the Chemotherapy Drugs for Timely Treatment of TNBC","authors":"Poulami Sarkar, Rashmi Chowdhary, Ashish Kumar Yadav, Neha Arya, Bharti Pandya, Vinay Kumar, J. Kanwar, Arshi Siddiqui, Roji Begum Khan","doi":"10.1055/s-0043-1774405","DOIUrl":null,"url":null,"abstract":"Abstract Objective  Worldwide, breast cancer is the most prevalent and common type of cancer. Physical examination and mammography with a range of sensitivities are currently used as screening methods. Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) gene expression. MicroRNAs (miRNA) as potential prognostic and diagnostic biomarkers, miRNA 125, 200c, 221, 21, and 34a were selected for study. Materials and Methods  Here, 25 consenting TNBC patients with negative ER/PR/HER-2 status and compatible history were accrued from the Department of Oncosurgery, All India Institutes of Medical Sciences (AIIMS) Bhopal. Serum from participants and 25 controls was collected for quantitative estimation of miRNA by quantitative real-time polymerase chain reaction. After being treated with epirubicin, capecitabine, and paclitaxel, the MDA-MB-231 cell line's expression of these miRNA subtypes was also examined. Results  miRNA125 ( p < 0.0001) and miRNA21 ( p < 0.05) were found to be statistically significant. miR125 (ΔCt [cycle threshold] 2.77) was seen to be upregulated and miR21 (ΔCt -1.61) was seen to be downregulated in TNBC patients. Epirubicin treatment caused miR125 to be downregulated, but capecitabine treatment caused miR125 to be upregulated. Paclitaxel was seen to downregulate miR21. All three chemotherapeutic agents were seen to downregulate miR34a. Conclusion  miRNAs can be developed into a reliable biomarker and prognostic tool with more research. They can also help develop and improve pharmaco-therapeutic strategies.","PeriodicalId":16149,"journal":{"name":"Journal of Laboratory Physicians","volume":"313 1","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laboratory Physicians","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1774405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Objective  Worldwide, breast cancer is the most prevalent and common type of cancer. Physical examination and mammography with a range of sensitivities are currently used as screening methods. Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) gene expression. MicroRNAs (miRNA) as potential prognostic and diagnostic biomarkers, miRNA 125, 200c, 221, 21, and 34a were selected for study. Materials and Methods  Here, 25 consenting TNBC patients with negative ER/PR/HER-2 status and compatible history were accrued from the Department of Oncosurgery, All India Institutes of Medical Sciences (AIIMS) Bhopal. Serum from participants and 25 controls was collected for quantitative estimation of miRNA by quantitative real-time polymerase chain reaction. After being treated with epirubicin, capecitabine, and paclitaxel, the MDA-MB-231 cell line's expression of these miRNA subtypes was also examined. Results  miRNA125 ( p < 0.0001) and miRNA21 ( p < 0.05) were found to be statistically significant. miR125 (ΔCt [cycle threshold] 2.77) was seen to be upregulated and miR21 (ΔCt -1.61) was seen to be downregulated in TNBC patients. Epirubicin treatment caused miR125 to be downregulated, but capecitabine treatment caused miR125 to be upregulated. Paclitaxel was seen to downregulate miR21. All three chemotherapeutic agents were seen to downregulate miR34a. Conclusion  miRNAs can be developed into a reliable biomarker and prognostic tool with more research. They can also help develop and improve pharmaco-therapeutic strategies.
未揭示miRNA在TNBC成功治疗中的作用:探索及时治疗TNBC的化疗药物的初步研究
摘要目的乳腺癌是世界范围内发病率最高、最常见的癌症类型。具有一系列敏感性的体格检查和乳房x光检查目前被用作筛查方法。三阴性乳腺癌(TNBC)缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER-2)基因表达。MicroRNAs (miRNA)作为潜在的预后和诊断生物标志物,选择miRNA 125、200c、221、21和34a进行研究。材料和方法本研究从全印度医学科学研究所(AIIMS)博帕尔肿瘤外科收集了25例经同意的ER/PR/HER-2阴性和相容病史的TNBC患者。收集参与者和25名对照者的血清,通过实时定量聚合酶链反应对miRNA进行定量估计。经表柔比星、卡培他滨和紫杉醇处理后,检测MDA-MB-231细胞系这些miRNA亚型的表达。结果miRNA125 (p < 0.0001)、miRNA21 (p < 0.05)差异有统计学意义。在TNBC患者中,miR125 (ΔCt[周期阈值]2.77)上调,miR21 (ΔCt -1.61)下调。表柔比星治疗导致miR125下调,卡培他滨治疗导致miR125上调。紫杉醇可下调miR21。所有三种化疗药物均下调miR34a。结论随着研究的深入,mirna可作为一种可靠的生物标志物和预后工具。它们还可以帮助开发和改进药物治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Laboratory Physicians
Journal of Laboratory Physicians MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
99
审稿时长
31 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信